Testing solutions designed for oncologists
We have developed a suite of products designed to work for every patient, even as cancers evolve. Our test menu is regularly updated to provide solutions that align to the latest evidence and guidelines.
State-of-the-art testing options
Includes DNA - and RNA-based next-generation sequencing (NGS)
Pan-tumor and disease-specific panels
A suite of panels to match the right test to the right indication
Solid tumor liquid biopsy testing
To provide minimally invasive genomic testing solutions
Specimen procurement services
Mobile phlebotomy and solid tissue block retrieval serviced included
Patient support teams
Partnering with you to help your patients navigate their testing journey
Testing solutions by disease area
Breast cancer
Lung cancer
Colorectal cancer
Hematologic cancer
Gastric cancer
Gynecologic cancer
Pan-Solid Tumor
Featured tests
NEO PanTracer Tissue + HRD
NGS comprehensive genomic profile targeting 517 genes in DNA and RNA for SNVs, InDels, CNVs, RNA fusions/splice variants with MSI and TMB for pan-solid tumors, and HRD for ovarian tumors.
NEO PanTracer Tissue (formerly Neo Comprehensive - Solid Tumor)
NGS comprehensive genomic profile targeting 517 genes in DNA and RNA for SNVs, InDels, CNVs, RNA fusions/splice variants with MSI and TMB for pan-solid tumors.
NEO PanTracer LBx
Liquid biopsy NGS comprehensive genomic profile targeting 514 genes for SNVs, InDels, CNVs, and fusions with MSI-High and bTMB for advanced stage pan-solid tumors.
Neo Comprehensive - Myeloid Disorders
The Neo Comprehensive - Myeloid Disorders assay analyzes 164 genes to detect DNA and RNA alterations through NGS for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance of myeloid neoplasms.